Evidence map›Paper›PMID 39574216›Full record

ArticleCardio-oncology (London, England)2024

Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis.

Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ryo IzumiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Toru HashimotoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan. hashimoto.toru.655@m.kyushu-u.ac.jp.
Hiroshi KisanukiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Kei IkutaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Wataru OtsuruDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Soshun AsakawaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Shoei YamamotoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Kayo MisumiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Takeo FujinoDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Keisuke ShinoharaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Shouji MatsushimaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Kazuya HosokawaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Shunsuke KatsukiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Taro MoriDepartment of Anatomic Pathology, Pathological Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Mikiko HashisakoDepartment of Anatomic Pathology, Pathological Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yuki TateishiDepartment of Anatomic Pathology, Pathological Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takeshi IwasakiDepartment of Anatomic Pathology, Pathological Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshinao OdaDepartment of Anatomic Pathology, Pathological Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shintaro KinugawaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.
Kohtaro AbeDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Clinical Research Building B 416, Higashi-Ku, Fukuoka, 812-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.

Indexed as

Cardiogenic shockFulminant myocarditisImmune checkpoint inhibitors,Immune-related adverse eventsMechanical circulatory supportVentricular arrhythmia

Identifiers

PMID39574216
PMCPMC11580468

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.